Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future

<div>Dose-response cytotoxic assay of STAT3 or AKT inhibition in BC3 and BCBL1 PEL cells treated with AG490 (AG) (Calbiochem) or LY294002 (LY) (Santa Cruz), respectively, at the indicated doses. Trypan blue exclusion assays were performed after 24 hours of treatment. Mean ± SD of three experiments is reported.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future 